Eli Lilly and Company (NYSE:LLY) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share guidance of $4.15-4.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.16. The company issued revenue guidance of $22.4-22.7 billion, compared to the consensus revenue estimate of $22.51 billion.

A number of brokerages have recently issued reports on LLY. Leerink Swann boosted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a market perform rating in a research report on Monday. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a sell rating in a research report on Monday, October 16th. Piper Jaffray Companies reissued a buy rating and issued a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Barclays PLC boosted their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an overweight rating in a research report on Friday, October 13th. Finally, Credit Suisse Group cut shares of Eli Lilly and from an outperform rating to a neutral rating and boosted their target price for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $89.12.

Eli Lilly and Company (NYSE:LLY) opened at 87.18 on Tuesday. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09. The company has a market cap of $91.97 billion, a PE ratio of 37.72 and a beta of 0.34. The stock has a 50 day moving average of $84.58 and a 200-day moving average of $82.25.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the company posted $0.88 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.39%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 990,000 shares of company stock valued at $82,949,650. Corporate insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/eli-lilly-and-company-lly-updates-fy17-earnings-guidance.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.